Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM - nejm.org

Original Article from The New England Journal of Medicine — Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

From the BloombergKimmel Institute for Cancer Immunotherapy, Johns Hopkins Kimmel Cancer Center, Baltimore (P.M.F., S.R.B., J.R.B., J.M.T.); McGill University Health Center (J.S.), and Centre Hospita… [+1501 chars]

full article...